Demircan Niyazi Volkan, Bese Nuran
Department of Radiation Oncology, Acıbadem Altunizade Hospital, İstanbul, Turkey.
MAA Acıbadem University Research Institute of Senology, İstanbul, Turkey.
Eur J Breast Health. 2023 Dec 27;20(1):1-7. doi: 10.4274/ejbh.galenos.2023.2023-11-4. eCollection 2024 Jan.
Breast cancer stands as the most prevalent malignancy, necessitating a well-established approach to its management due to its sustained prevalence over decades. The implementation of intensive treatments, combining various modalities, has yielded excellent survival outcomes. Consequently, the optimization of quality of life and the mitigation of long-term side effects emerge as critical considerations for clinicians. As a result, discussions regarding treatment de-intensification strategies have been initiated for all treatment modalities, including surgery, radiotherapy (RT), and chemotherapy. RT plays a crucial role in adjuvant therapy. The efficacy of RT in disease control and overall survival across all stages of breast cancer has been demonstrated in numerous clinical trials and meta-analyses utilizing extensive datasets. However, advancements in genetic tumor profiling and improved identification of disease subgroups have prompted a reevaluation of RT omission in low-risk groups as a strategy for treatment de-intensification. Conversely, technological improvements and shortened total treatment times with hypofractionation make RT a secure and feasible option for enhancing local control and survival with minimal impact on the quality of life.
乳腺癌是最常见的恶性肿瘤,由于其数十年来持续高发,因此需要一种成熟的治疗方法。采用多种方式的强化治疗已取得了出色的生存结果。因此,优化生活质量和减轻长期副作用已成为临床医生的关键考量因素。结果,针对包括手术、放疗(RT)和化疗在内的所有治疗方式,都已展开了关于治疗降强度策略的讨论。放疗在辅助治疗中起着至关重要的作用。利用大量数据集进行的众多临床试验和荟萃分析已证明,放疗在乳腺癌各阶段的疾病控制和总体生存方面均具有疗效。然而,基因肿瘤分析的进展以及对疾病亚组的更好识别促使人们重新评估将低风险组省略放疗作为一种治疗降强度策略的做法。相反,技术进步以及采用大分割放疗缩短了总治疗时间,使得放疗成为一种安全可行的选择,既能增强局部控制和提高生存率,又能对生活质量产生最小影响。